Профилактика кровотечений и фармакокинетика фактора свертывания крови VIII у детей с тяжелой гемофилией А

Обложка

Цитировать

Полный текст

Об авторах

Вячеслав Васильевич Дмитриев

Республиканский научно-практический центр детской онкологии, гематологии и иммунологии Минздрава Республики Беларусь

Автор, ответственный за переписку.
Email: dmitrievhaematol@mail.ru
Россия

Людмила Ивановна Волкова

Белорусская медицинская академия последипломного образования Минздрава Республики Беларусь

Email: luidmila_volkova@mail.ru
Россия

Евгений Вячеславович Дмитриев

Республиканский научно-практический центр детской онкологии, гематологии и иммунологии Минздрава Республики Беларусь

Россия

Список литературы

  1. Ahlberg A. Haemophilia in Sweden. VII. Incidence, treatment and prophylaxis of arthropathy and other musculo-skeletal manifestations of haemophilia A and B. Acta Orthopaedica Scand. 1965;(Suppl 77):1-98.
  2. Nilsson IM, Blomback M, Ahlberg A. Our experience in Sweden with prophylaxis on haemophilia. Proceedings of the 5th Congress of the World Federation of Hemophilia, Montreal 1968; Bibl Haematol, No. 34. New York: Karger, 1970;111 -24.
  3. Björkman S. Prophylactic dosing of factor VIII and factor IX from a clinical pharmacokinetic perspective. Haemophilia. 2003;9(Suppl. 1):101-8; discussion 109-10.
  4. Collins PW, Blanchette VS, Fischer K, Björkman S, Oh M, Fritsch S, et al. Break-through bleeding in relation to predicted factor VIII levels in patients receiving prophylactic treatment for severe hemophilia A. J Thromb Haemost. 2009;7(3): 413-20.
  5. Collins PW, Fischer K, Morfini M, Blanchette VS, Björkman S; International Prophylaxis Study Group Pharmacokinetics Expert Working Group. Implications of coagulation factor VIII and IX pharmacokinetics in the prophylactic treatment of haemophilia. Haemophilia. 2011;17(1):2-10.
  6. Björkman S, Berntorp E. Pharmacokinetics of coagulation factors: clinical relevance for patients with haemophilia. Clin Pharmacokinet. 2001 ;40(11): 815-32.
  7. Björkman S, Oh M, Spotts G, Schroth P, Fritsch S, Ewenstein BM, et al. Population pharmacokinetics of recombinant factor VIII: the relationships of pharmacokinetics to age and body weight. Blood. 2012;119(2):612-8.
  8. Hay CR, Broun S, Collins PW, Keeling DM, Liesner R. The diagnosis and management of factor VIII and IX inhibitots: a guideline from the United Kingdom Hemophilia Centre Doctors Organisation. Br J Haematol. 2006; 133(6) :591 -605.
  9. Collins PW, Björkman S, Fischer K, Blanchette V, Oh M, Schroth P, et al. Factor VIII requirement to maintain a target plasma level in the prophylactic treatment of severe hemophilia A: influences of variance in pharmacokinetics and treatment regimens. J Thromb Haemost. 2010 Feb;8(2):269-75. doi: 10.1111/j.1538-7836. 2009.03703.x. Epub 2009 Nov 23.
  10. Morfini M, Lee M, Messori A. The design and analysis of half-life and recovery studies for factor VIII and factor IX. Factor VIII/Factor IX Scientific and Standardization Committee of the International Society for Thrombosis and Haemostasis. Thromb Haemost. 1991;66(3):384-6.
  11. Lee M, Morfini M, Schulman S, Ingerslev J; Factor VIII/Factor IX Scientific and Standardization Committee of the International Society for Thrombosis and Haemostasis. Scientific and Standardization Committee Communication. The design and analysis of pharmacokinetic studies of coagulation Factors. On behalf of the Subcommittee on Factor VIII and Factor IX of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Available at: http://c.ymcdn.com/sites/www.isth.org/resource/ group/d4a6f49a-f4ec-450f-9e0f-7be9f0c2ab2e/official_communications/ fviiipharmaco.pdf.

Дополнительные файлы

Доп. файлы
Действие
1. JATS XML
Скачать

© Дмитриев В.В., Волкова Л.И., Дмитриев Е.В., 2016

Creative Commons License
Эта статья доступна по лицензии Creative Commons Attribution 4.0 International License.